Q32 Bio is a clinical stage biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/29/20 | $60,000,000 | Series B |
Acorn Bioventures OrbiMed Advisors | undisclosed |
